| Ezetimibe and vascular inflammation. | |
| | |
MedLine Citation:
|
PMID: 21044014 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
Atherosclerosis is an inflammation-based complex vascular disorder which causes coronary artery disease, stroke and peripheral artery disease. Its pathophysiological process consists of endothelial dysfunction, monocyte adhesion to endothelial cells, lipid and inflammatory cell accumulation in the vascular wall, and migration and proliferation of smooth muscle cells. Both hyperlipidemia and inflammation are profoundly involved in each step. Cholesterol lowering by HMG-CoA reductase (statin) is beneficial for treating atherosclerotic coronary artery disease and stroke, together with reducing a surrogate-marker of inflammation, C-reactive protein (CRP). Another recently established cholesterol lowering tool using an intestinal cholesterol absorption inhibitor, ezetimibe, has been applied for clinical treatment of hypercholesterolemia for several reasons. First, hypercholesterolemia is associated with increased intestinal cholesterol absorption. Second, low cholesterol absorption prevents cardiovascular events. Third, cholesterol metabolism analysis provides evidence that the long-term use of statin increases cholesterol absorption. In terms of low-density lipoprotein cholesterol (LDL-C) and CRP reductions, the more powerful effect of ezetimibe has been seen when the agent is combined with statins. However, the effect of ezetimibe monotherapy on CRP reduction has not been well defined. This review provides information on recently described clinical trials of ezetimibe monotherapy, stain monotherapy, and combined therapy for LDL-C lowering and vascular inflammation. |
| | |
Authors:
|
Toshiyuki Ishibashi; Yasuchika Takeishi |
Related Documents
:
|
1596304 - Is fat restriction needed with hmgcoa reductase inhibitor treatment? 19895944 - High-density lipoprotein cholesterol as a risk factor and target of therapy after acute... 16503864 - Hmg-coa reductase inhibitors: effects on chronic subacute inflammation and onset of ath... 11926854 - A community-wide survey of physician practices and attitudes toward cholesterol managem... 20487904 - Effects of maternal thiamine deficiency on the lipid composition of rat whole brain, gr... 7020984 - Alcohol intake, cigarette smoking and plasma lipids and lipoproteins in 12--19-year-old... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Current vascular pharmacology Volume: 9 ISSN: 1875-6212 ISO Abbreviation: Curr Vasc Pharmacol Publication Date: 2011 Jan |
Date Detail:
|
Created Date: 2010-11-16 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101157208 Medline TA: Curr Vasc Pharmacol Country: United Arab Emirates |
Other Details:
|
Languages: eng Pagination: 99-108 Citation Subset: IM |
Affiliation:
|
Department of Cardiology and Hematology, Fukushima Medical University, 1 Hikarigaoka, Fukushima 960-1295, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Cell reprogramming: a new chemical approach to stem cell biology and tissue regeneration.
Next Document: Ezetimibe and reactive oxygen species.